Cancer survivor rates are tragic stories of those who did not survive are invoked on both sides of the health care debate? Does reform promise to treat the untreated or will it threaten new and exciting technologies. Dr. Nicholas Vogelzang now directs research for U.S. Oncology - the parent company of the Comprehensive Cancer Centers of Nevada and he previously headed the Nevada Cancer Institute. Vogelzang gives us his take on how cancer treatment fits into the reform debate.

Support comes from

KNPR and NPR Thank-You Gifts including t-shirts hoodies and cap

More Stories